We should be seeing an ODD for CRAO by week of Feb 23rd. Possible for next week based on timing of other company approvals, but more likely for the week after. Even small revenue contracts for Lympro at this stage would do wonders for this company. Other catalysts like the ODD above would likely hold gains if we had even modest sales. On the Eltoprazine front, I believe there has to be a grant or partner - likely grant. IND's (and obviously trials) are expensive and I am quite sure that is what the wait has been for Eltoprazine.